调节染色质的癌基因有利于对免疫疗法做出反应

IF 7.2 2区医学

Oncoimmunology Pub Date : 2024-01-09 DOI:10.1080/2162402x.2024.2303195

Leqian Ying, Zhangmin Hu, Yi Lu, Qing Tao, Fen Xiong, Yongqian Shu, Yufei Yang, Xuehan Qiao, Chen Peng, Yuchun Jiang, Miao Han, Min Xu, Xiaoqin Li, Deqiang Wang

引用次数: 0

摘要

许多与细胞功能和命运相关的生物过程都始于染色质的改变，而与免疫检查点抑制剂（ICIs）疗效相关的许多因素实际上都是由染色质改变引起的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

An oncogene regulating chromatin favors response to immunotherapy

Many biological processes related to cell function and fate begin with chromatin alterations, and many factors associated with the efficacy of immune checkpoint inhibitors (ICIs) are actually downs...

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Oncoimmunology ONCOLOGY-IMMUNOLOGY

CiteScore

12.80

自引率

2.80%

发文量

276

期刊介绍： Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.